	US 12,258,405 B2
	CD3 antibody and pharmaceutical use thereof
Hua Ying, Shanghai (CN); Ling Zhang, Shanghai (CN); Xiaoying Yang, Shanghai (CN); Hu Ge, Shanghai (CN); and Weikang Tao, Shanghai (CN)
Assigned to Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
Appl. No. 17/298,703
Filed by Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
PCT Filed Dec. 6, 2019, PCT No. PCT/CN2019/123548 § 371(c)(1), (2) Date Jun. 1, 2021, PCT Pub. No. WO2020/114478, PCT Pub. Date Jun. 11, 2020.
Claims priority of application No. 201811491781.3 (CN), filed on Dec. 7, 2018.
Prior Publication US 2022/0242953 A1, Aug. 4, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)]

14 Claims

1. An antibody or antigen-binding fragment thereof specifically binding to human CD3, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein:

the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NOs: 48, 49 and 50, respectively, and

the heavy chain variable region is any one selected from the group consisting of the following i) to v):

i) a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 37, 40 and 42, respectively;

ii) a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 37, 47 and 45, respectively;

iii) a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 37, 38 and 39, respectively;

iv) a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 37, 40 and 43, respectively; and

v) a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NOs: 37, 40 and 41, respectively.